Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...

On Wednesday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.59 which represents a decrease of $-0.07 or -10.61% from the prior close of $0.66. The stock opened at $0.65 and ...

Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...

Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to ...

Seres Therapeutics (NASDAQ:MCRB) is scheduled to announce Q3 earnings results on Wednesday, November 13th, before market open ...

Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had ...

On Tuesday, Seres Therapeutics Inc (MCRB) stock saw a modest uptick, ending the day at $0.77 which represents a slight increase of $0.07 or 10.00% from the prior close of $0.7. The stock opened at $0.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Short interest in Seres Therapeutics Inc (NASDAQ:MCRB) increased during the last reporting period, rising from 15.94M to 17.22M. This put 15.76% of the company's publicly available shares short.

Long-term investors should consider making these Fidelity mutual funds the core of their portfolio.